On February 19 at Morehouse College in Atlanta, LIXTE Biotechnology Holdings Inc. will serve as the lead sponsor of the Good Health: Mind, Body & Soul Summit, an invitation-only forum uniting health experts, cultural influencers and community leaders. By funding the event inspired by De La Soul’s legacy and partnered with Blacksmith Holdings, LIXTE positions its brand alongside a wellness-focused cultural initiative that targets health equity for Black men and families. The company’s CEO, Geordan Pursglove, will deliver opening remarks highlighting the clinical promise of LB-100, LIXTE’s first-in-class PP2A inhibitor. Attendance by roughly 150 stakeholders—including oncologists, public health advocates and grassroots organizers—offers LIXTE a platform to discuss its pipeline and social impact strategy, potentially enhancing its reputation among patient advocacy groups and ethically driven investors.

On January 28–29, LIXTE’s Chief Executive Officer, Geordan Pursglove, will attend the DealFlow Discovery Conference at The Borgata Hotel, Casino & Spa in Atlantic City. During pre-scheduled one-on-one sessions, Pursglove plans to update institutional and family-office investors on proof-of-concept trials of LB-100 in ovarian clear cell carcinoma, metastatic colon cancer and advanced soft tissue sarcoma. He will also outline timelines for interim safety readouts expected in Q2 and discuss preliminary pharmacodynamic biomarkers showing target engagement in 80% of patients at the 1.5 mg/m2 dose. These meetings follow published preclinical data demonstrating up to 60% tumor growth inhibition in combination with standard chemotherapy, offering investors a detailed view of LIXTE’s clinical milestones and regulatory pathway toward potential fast-track designation.